Review Article
Background: Three-dimensional (3D) printing is emerging as a versatile pharmaceutical manufacturing technology capable of producing personalized dosage forms with tailored drug loading, geometry, and release characteristics.
Scope: This review summarizes recent advances in pharmaceutical 3D-printing technologies, including fused deposition modeling (FDM), selective laser sintering (SLS), stereolithography (SLA), and hybrid approaches, with particular emphasis on personalized dosage forms, controlled drug release, and multi-drug polypills.
Key Findings: Recent studies demonstrate the ability of 3D printing to achieve programmable drug-release profiles and individualized dosing. Notably, hybrid SLS–FDM tablets have demonstrated approximately 12 h of controlled drug release with near-zeroorder kinetics, highlighting the potential for precise modulation of drug liberation. Clinical application in maple syrup urine disease (MSUD) has also demonstrated improved control of blood leucine concentrations using individualized 3D-printed dosage forms. Furthermore, 3D-printed polypills have demonstrated the feasibility of incorporating multiple drugs into a single dosage form with tailored release characteristics.
Main Challenges: Despite these advances, translation into routine pharmaceutical manufacturing remains constrained by relatively low production throughput compared with conventional tablet compression, formulation and material limitations, dose uniformity, process reproducibility, scalability, quality control, regulatory requirements, and limited commercial adoption.
Outlook: Future research should focus on increasing printing speed and manufacturing scalability, establishing robust process-validation and regulatory frameworks, and generating stronger clinical evidence. Integration of digital manufacturing with personalized dosing and advanced drug-release design could position 3D printing as a valuable platform for patient-specific pharmaceutical therapy.
Loading publication timeline...